<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput xmlns:ns2="local"><serviceExecutionTime>287</serviceExecutionTime><Deal id="148996"><Title>CeMM and University of Oxford to develop S-enantiomer of crizotinib for the treatment of cancer </Title><CompanyPrincipal id="1063620">CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences</CompanyPrincipal><CompanyPartner id="22182">University of Oxford</CompanyPartner><Type>Drug - Early Research/Development</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1542529</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="651">Cancer</Indication></Indications><ActionsPrimary><Action id="58260">7,8 dihydro 8 oxoguanine triphosphatase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><DateStart>2014-04-02T00:00:00Z</DateStart><DateEventMostRecent>2014-04-02T00:00:00Z</DateEventMostRecent><Drugs><Drug id="90682"><DrugNameDisplay>NUDT1 inhibitors (cancer), CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences/Karolinska Institutet/University of Oxford</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="NDR">No Development Reported</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;By April 2014, the &lt;ulink linkType="Company" linkID="1063620"&gt;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences&lt;/ulink&gt;, the &lt;ulink linkType="Company" linkID="22182"&gt;University of Oxford&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="21110"&gt;Karolinska Institute&lt;/ulink&gt; had collaborated on the development of &lt;ulink linkType="Drug" linkID="90682"&gt;S-enantiomer of crizotinib&lt;/ulink&gt; for the potential treatment of cancer [&lt;ulink linkType="Reference" linkID="1542529"&gt;1542529&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2014-04-02T00:00:00Z</Date><Drugs><DrugLink id="90682" nameDisplay="NUDT1 inhibitors (cancer), CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences/Karolinska Institutet/University of Oxford"></DrugLink></Drugs><Stage id="PC">Preclinical</Stage><StageNotes>&lt;para&gt;S-enantiomer of crizotinib is in preclinical development &lt;/para&gt;</StageNotes><Summary>&lt;para&gt;By April 2014, the &lt;ulink linkType="Company" linkID="1063620"&gt;CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences&lt;/ulink&gt;, the &lt;ulink linkType="Company" linkID="22182"&gt;University of Oxford&lt;/ulink&gt; and the &lt;ulink linkType="Company" linkID="21110"&gt;Karolinska Institute&lt;/ulink&gt; had collaborated on the development of &lt;ulink linkType="Drug" linkID="90682"&gt;S-enantiomer of crizotinib&lt;/ulink&gt; for the potential treatment of cancer. The project research was funded by the&lt;ulink linkType="Company" linkID="1063435"&gt; Austrian Academy of Sciences&lt;/ulink&gt;, the GEN-AU initiative of the Austrian Federal Ministry of Science and Research and the &lt;ulink linkType="Company" linkID="1045801"&gt;EU&lt;/ulink&gt; project “ASSET”. Further financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="1542529"&gt;1542529&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1063620" type="Company"><TargetEntity id="5036352089" type="organizationId">CeMM Forschungszentrum Fuer Molekulare Medizin GmbH</TargetEntity></SourceEntity><SourceEntity id="22182" type="Company"><TargetEntity id="5000698033" type="organizationId">University of Oxford</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="58260" type="Action"><TargetEntity id="4826" type="Mechanism">7,8-Dihydro-8-Oxoguanine Triphosphatase (NUDT1; MTH1) Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="152615"><Title>GeneSegues and US government to develop passive topical DNA vaccine against VEEV   </Title><CompanyPrincipal id="1004475">GeneSegues Therapeutics</CompanyPrincipal><CompanyPartner id="20516">US Government</CompanyPartner><Type>Drug - Early Research/Development</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="=" max="2.6" min="2.6"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1627192</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.3" usdExchangeRate="1.0" usdExchangeRatePeriod="2014 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1627192</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.3" usdExchangeRate="1.0" usdExchangeRatePeriod="2014 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="1287">Venezuelan equine encephalitis virus infection</Indication></Indications><ActionsSecondary><Action id="991">Antiviral</Action><Action id="1879">DNA vaccine</Action></ActionsSecondary><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="1667">Nanoparticle formulation dermatological</Technology></Technologies><DateStart>2014-12-18T00:00:00Z</DateStart><DateEventMostRecent>2014-12-18T00:00:00Z</DateEventMostRecent><Drugs><Drug id="94722"><DrugNameDisplay>DNA vaccine (topical, VEE virus infection), GeneSegues/USAMRIID</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In December 2014, &lt;ulink linkType="Company" linkID="1004475"&gt;GeneSegues Therapeutics&lt;/ulink&gt; signed a contract with &lt;ulink linkType="Company" linkID="1041322"&gt;US Defense Threat Reduction Agency&lt;/ulink&gt; (DTRA) to collaborate with &lt;ulink linkType="Company" linkID="14184"&gt;US Army Medical Research Institute of Infectious Disease&lt;/ulink&gt; (USAMRIID) to develop &lt;ulink linkType="Drug" linkID="94722"&gt;passive topical DNA vaccine&lt;/ulink&gt; against Venezuelan equine encephalitis virus (VEEV)  [&lt;ulink linkType="Reference" linkID="1627192"&gt;1627192&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2014-12-18T00:00:00Z</Date><Drugs><DrugLink id="94722" nameDisplay="DNA vaccine (topical, VEE virus infection), GeneSegues/USAMRIID"></DrugLink></Drugs><Stage id="DR">Discovery</Stage><StageNotes>&lt;para&gt;GeneSegues will perform preclinical studies with USAMRIID to encapsulate and optimize USAMRIID’s DNA antigen.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In December 2014, &lt;ulink linkType="Company" linkID="1004475"&gt;GeneSegues Therapeutics&lt;/ulink&gt; signed a contract with &lt;ulink linkType="Company" linkID="1041322"&gt;US Defense Threat Reduction Agency&lt;/ulink&gt; (DTRA) to collaborate with &lt;ulink linkType="Company" linkID="14184"&gt;US Army Medical Research Institute of Infectious Disease&lt;/ulink&gt; (USAMRIID) to develop &lt;ulink linkType="Drug" linkID="94722"&gt;passive topical DNA vaccine&lt;/ulink&gt; against Venezuelan equine encephalitis virus (VEEV). GeneSegues would execute preclinical studies with USAMRIID to encapsulate and optimize USAMRIID’s DNA antigen within GeneSegues’ proprietary sub-50 nanometer capsules that can passively cross the epithelial skin barrier and target the rich immune system that resides just beneath the surface. The award has a one-year period of performance with a value of $550,000, including two option periods that extend the award to 30 months and $1.3 million if all options are exercised [&lt;ulink linkType="Reference" linkID="1627192"&gt;1627192&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="20516" type="Company"><TargetEntity id="8589934522" type="organizationId">United States of America (Government)</TargetEntity></SourceEntity><SourceEntity id="1004475" type="Company"><TargetEntity id="4297875350" type="organizationId">GeneSegues Inc</TargetEntity></SourceEntity><SourceEntity id="1287" type="ciIndication"><TargetEntity id="A92.2" type="ICD10"></TargetEntity><TargetEntity id="10014611" type="MEDDRA"></TargetEntity><TargetEntity id="D004685" type="MeSH"></TargetEntity><TargetEntity id="-2097213265" type="omicsDisease"></TargetEntity><TargetEntity id="2844" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="152622"><Title>SPIMACO to commercialize Roche's Herceptin and Mabthera products in Saudi Arabia  </Title><CompanyPrincipal id="19446">Roche Holding AG</CompanyPrincipal><CompanyPartner id="1045863">Saudi Pharmaceutical Industries &amp; Medical Appliances Corp</CompanyPartner><Type>Drug - Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="SA">Saudi Arabia</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1627222</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="49">Breast tumor</Indication></Indications><ActionsPrimary><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="962">Biosimilar product</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><DateStart>2015-01-13T00:00:00Z</DateStart><DateEventMostRecent>2015-01-13T00:00:00Z</DateEventMostRecent><Drugs><Drug id="6736"><DrugNameDisplay>rituximab</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="6386"><DrugNameDisplay>trastuzumab</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In January 2015, &lt;ulink linkType="Company" linkID="1045863"&gt;Saudi Pharmaceutical Industries &amp;amp; Medical Appliances&lt;/ulink&gt; (SPIMACO) signed a five year agreement with &lt;ulink linkType="Company" linkID="19446"&gt;Hoffmann-La Roche&lt;/ulink&gt; to manufacture, sell and distribute &lt;ulink linkType="Drug" linkID="6386"&gt;Herceptin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6736"&gt;Mabthera&lt;/ulink&gt; products in Saudi Arabia  [&lt;ulink linkType="Reference" linkID="1627222"&gt;1627222&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2015-01-13T00:00:00Z</Date><Drugs><DrugLink id="6386" nameDisplay="trastuzumab"></DrugLink><DrugLink id="6736" nameDisplay="rituximab"></DrugLink></Drugs><Stage id="R">Registered</Stage><StageNotes>&lt;para&gt;Both drugs are approved in U.S., Europe and many other countries.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In January 2015, &lt;ulink linkType="Company" linkID="1045863"&gt;Saudi Pharmaceutical Industries &amp;amp; Medical Appliances&lt;/ulink&gt; (SPIMACO) signed a five year agreement with &lt;ulink linkType="Company" linkID="19446"&gt;Hoffmann-La Roche&lt;/ulink&gt; to manufacture, sell and distribute &lt;ulink linkType="Drug" linkID="6386"&gt;Herceptin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6736"&gt;Mabthera&lt;/ulink&gt; products in Saudi Arabia. The contract has the option for renewal. Financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="1627222"&gt;1627222&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="6736" type="Drug"><TargetEntity id="204337" type="siDrug">Rituximab</TargetEntity></SourceEntity><SourceEntity id="6386" type="Drug"><TargetEntity id="198466" type="siDrug">Trastuzumab</TargetEntity></SourceEntity><SourceEntity id="1045863" type="Company"><TargetEntity id="4295887324" type="organizationId">Saudi Pharmaceutical Industries and Medical Appliances Corp SJSC</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3756" type="Action"><TargetEntity id="1223" type="Mechanism">HER2 (erbB2) Inhibitors</TargetEntity><TargetEntity id="1820" type="Mechanism">Anti-HER2/neu/ErbB2</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="247673"><Title>Kiniksa Pharmaceuticals to develop and commercialize Medimmune's mavrilimumab for all indications worldwide </Title><CompanyPrincipal id="18008">MedImmune LLC</CompanyPrincipal><CompanyPartner id="1123466">Kiniksa Pharmaceuticals Ltd</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="8.0" min="8.0"></ValuePaid><ValueProjected accuracy="&gt;" max="2531.0" min="16.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>2046748</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2017 Q3">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>2046748</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="8.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>2046748</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="72.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Sales Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1185.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="72.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>2046748</Reference><Type>Sales Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1185.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>2046748</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2017 Q3">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>2046748</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="8.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2017 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><ActionsPrimary><Action id="16995">VEGF gene inhibitor</Action><Action id="2400">Metalloprotease-3 inhibitor</Action><Action id="2460">Metalloprotease-1 inhibitor</Action><Action id="15031">C-reactive protein inhibitor</Action><Action id="35686">Small inducible cytokine A17 ligand inhibitor</Action><Action id="672">GM-CSF receptor antagonist</Action><Action id="37008">Hemoglobin scavenger receptor antagonist</Action><Action id="51076">Chemokine CC22 ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="892">IL-6 modulator</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><DateStart>2017-12-21T00:00:00Z</DateStart><DateEventMostRecent>2017-12-21T00:00:00Z</DateEventMostRecent><Drugs><Drug id="32953"><DrugNameDisplay>mavrilimumab</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C2">Phase 2 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In December 2017, &lt;ulink linkType="Company" linkID="1123466"&gt;Kiniksa Pharmaceuticals&lt;/ulink&gt; entered into an exclusive license agreement with &lt;ulink linkType="Company" linkID="18008"&gt;Medimmune&lt;/ulink&gt; to develop and commercialize &lt;ulink linkType="Drug" linkID="32953"&gt;mavrilimumab&lt;/ulink&gt; and any other product containing an antibody to the GM-CSF receptor alpha for all indications worldwide  [&lt;ulink linkType="Reference" linkID="2046748"&gt;2046748&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2046753"&gt;2046753&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2017-12-21T00:00:00Z</Date><Drugs><DrugLink id="32953" nameDisplay="mavrilimumab"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="2046748">2046748</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2017 Q3" exchangeRateUS="1">8</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><StageNotes>&lt;para&gt;Mavrilimumab was in phase II trials for RA.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In December 2017, &lt;ulink linkType="Company" linkID="1123466"&gt;Kiniksa Pharmaceuticals&lt;/ulink&gt; entered into an exclusive license agreement with &lt;ulink linkType="Company" linkID="18008"&gt;Medimmune&lt;/ulink&gt; to develop and commercialize &lt;ulink linkType="Drug" linkID="32953"&gt;mavrilimumab&lt;/ulink&gt; and any other product containing an antibody to the GM-CSF receptor alpha for all indications worldwide.&lt;/para&gt;&lt;para&gt;- Mavrilimumab is human  monoclonal antibody  that bind and antagonize the GM-CSF receptor, as  a  sc therapy for rheumatoid arthritis and was in phase II trials.&lt;/para&gt;&lt;para&gt;- MedImmune has  withdrawn the IND for mavrilimumab for the treatment of RA and Kiniksa would develop mavrilimumab for the treatment of GCA under a new IND in the US and new Clinical Trial Application, in Europe, and plan to initiate a phase II clinical trial in 2018.&lt;/para&gt;&lt;para&gt;- Kiniksa also acquired non-exclusive licenses to other Medimmune technology for use in exploiting licensed products. &lt;/para&gt;&lt;para&gt;- Medimmune would receive upfront payment of $8 million and future clinical, regulatory and initial sales milestone payments of up to $72.5 million in the aggregate for the first two indications, including a milestone payment of $10 million upon the earlier to occur of a specified regulatory milestone and December 31, 2018, and clinical and regulatory milestone payments of up to $15 million in the aggregate for each subsequent indication.&lt;/para&gt;&lt;para&gt;- Kiniksa would pay milestone payments of up to $85 million upon the achievement of annual net sales thresholds up to, but excluding, $1 billion in annual net sales as well as additional milestone payments aggregating up to $1.1 billion upon the achievement of additional annual net sales thresholds starting at $1 billion and higher.&lt;/para&gt;&lt;para&gt;- Kiniksa would also pay tiered royalties on escalating tiers of annual net sales of licensed products starting in the low double-digit percentages and ending at twenty percent on the first commercial sale of licensed products [&lt;ulink linkType="Reference" linkID="2046748"&gt;2046748&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2046753"&gt;2046753&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="32953" type="Drug"><TargetEntity id="420139" type="siDrug">Mavrilimumab</TargetEntity><TargetEntity id="779459" type="siDrug">CAM-3003</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="1123466" type="Company"><TargetEntity id="5050920431" type="organizationId">Kiniksa Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2400" type="Action"><TargetEntity id="457" type="Mechanism">MMP-3 (Stromelysin 1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2460" type="Action"><TargetEntity id="454" type="Mechanism">MMP-1 (Interstitial Collagenase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="892" type="Action"><TargetEntity id="3055" type="Mechanism">IL-6 Modulators</TargetEntity></SourceEntity><SourceEntity id="672" type="Action"><TargetEntity id="3338" type="Mechanism">Anti-GM-CSF</TargetEntity></SourceEntity><SourceEntity id="16995" type="Action"><TargetEntity id="3346" type="Mechanism">VEGFA Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="15031" type="Action"><TargetEntity id="2959" type="Mechanism">C-Reactive Protein (CRP) Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="257321"><Title>Tenshindo to use ProBiotix' LPLDL in cardiovascular health in Japan</Title><CompanyPrincipal id="1172765">ProBiotix Health Ltd</CompanyPrincipal><CompanyPartner id="1130997">Tenshindo Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="JP">Japan</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>2170078</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>2170078</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="57">Cardiovascular disease</Indication><Indication id="655">Metabolic disorder</Indication><Indication id="684">Nutritional disorder</Indication></Indications><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="173474">Microbiome modulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1211">Nutrional supplements and vitamin deal</Technology></Technologies><DateStart>2019-07-03T00:00:00Z</DateStart><DateEventMostRecent>2019-07-03T00:00:00Z</DateEventMostRecent><Drugs><Drug id="103693"><DrugNameDisplay>Lactobacillus plantarum-based microbiome modulators (metabolism disorder/nutritional disorder), OptiBiotix</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In July 2019, &lt;ulink linkType="Company" linkID="1130997"&gt;Tenshindo&lt;/ulink&gt; entered into an agreement to use &lt;ulink linkType="Company" linkID="1172765"&gt;ProBiotix Health&lt;/ulink&gt;'s (a subsidiary of &lt;ulink linkType="Company" linkID="1109030"&gt;OptiBiotix Health&lt;/ulink&gt;) &lt;ulink linkType="Drug" linkID="103693"&gt;lactobacillus plantarum&lt;/ulink&gt; (LPLDL) in cardiovascular food supplements in Japan [&lt;ulink linkType="Reference" linkID="2170078"&gt;2170078&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2019-07-03T00:00:00Z</Date><Drugs><DrugLink id="103693" nameDisplay="Lactobacillus plantarum-based microbiome modulators (metabolism disorder/nutritional disorder), OptiBiotix"></DrugLink></Drugs><Stage id="DR">Discovery</Stage><StageNotes>&lt;para&gt;LPLDL is in preclinical.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In July 2019, &lt;ulink linkType="Company" linkID="1048786"&gt;Tenshindo&lt;/ulink&gt; entered into an agreement to use &lt;ulink linkType="Company" linkID="1172765"&gt;ProBiotix Health&lt;/ulink&gt;'s (a subsidiary of &lt;ulink linkType="Company" linkID="1109030"&gt;OptiBiotix Health&lt;/ulink&gt;) &lt;ulink linkType="Drug" linkID="103693"&gt;lactobacillus plantarum&lt;/ulink&gt; (LPLDL) in cardiovascular food supplements in Japan.&lt;/para&gt;&lt;para&gt;- ProBiotix' Lactobacillus plantarum is in discovery and is developed using optiscreen and optiBiotic technologies for the treatment of cardiovascular diseases.&lt;/para&gt;&lt;para&gt;- Financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="2170078"&gt;2170078&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1130997" type="Company"><TargetEntity id="5052138155" type="organizationId">Tenshindo Inc</TargetEntity></SourceEntity><SourceEntity id="1172765" type="Company"><TargetEntity id="5065978146" type="organizationId">ProBiotix Health Ltd</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="655" type="ciIndication"><TargetEntity id="10058097" type="MEDDRA"></TargetEntity><TargetEntity id="D008659" type="MeSH"></TargetEntity><TargetEntity id="-652126003" type="omicsDisease"></TargetEntity><TargetEntity id="961" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="684" type="ciIndication"><TargetEntity id="E63.9" type="ICD10"></TargetEntity><TargetEntity id="10003018" type="MEDDRA"></TargetEntity><TargetEntity id="D009748" type="MeSH"></TargetEntity><TargetEntity id="-21513915" type="omicsDisease"></TargetEntity><TargetEntity id="1266" type="siCondition"></TargetEntity></SourceEntity></CrossReferences></Deal></ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput>